Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Clinical treatment programs	$ 22	$ 23	$ 76	$ 106
Total revenues	22	23	76	106
Costs and expenses:
Production costs	272	353	830	1,232
Research and development	1,342	1,968	3,244	7,081
General and administrative	1,634	1,685	5,721	5,600
Total costs and expenses	3,248	4,006	9,795	13,913
Operating loss	(3,226)	(3,983)	(9,719)	(13,807)
Interest expense		(1)		(3)
Interest and other income/(expense)	40	181	156	343
Insurance proceeds from legal settlement, net	190		1,626
Gain (Loss) on sales of short term marketable securities	31		(56)
Gain from sale of income tax net operating losses			1,561	1,374
Redeemable warrants valuation adjustment	103		103
Net loss	(2,862)	(3,803)	(6,329)	(12,093)
Other comprehensive income (loss):
Reclassification adjustments for (gain) loss on sales of short term marketable securities included in net loss	(31)		56
Unrealized gain (loss) on marketable securities	15	(215)	112	(241)
Net comprehensive loss	$ (2,878)	$ (4,018)	$ (6,161)	$ (12,334)
Basic and diluted loss per share (in dollars per share)	$ (0.13)	$ (0.18)	$ (0.30)	$ (0.62)
Weighted average shares outstanding, basic and diluted (in shares)	21,832,940	20,564,538	21,046,418	19,358,962